Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

Haploidentical HCT for Severe Aplastic Anemia

A legfontosabb adatok

Ki végzi
St. Jude Children's Research Hospital
Hol
Memphis (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
21 fő, tervezett
Kezdés
2021. jan. 21.
Várható befejezés
2030. júl. 1.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Anti-Thymocyte Globulin (Rabbit)
  • Fludarabine
  • Cyclophosphamide
  • Mesna
  • G-CSF
  • Total Lymphoid Irradiation (TLI)
  • CliniMACS
  • HPC, A Infusion
  • CD45RA-depleted DLI
A regiszteradat frissítve
2026. szeptember 16.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for children and young people with severe aplastic anemia or a single lineage cytopenia (one blood cell type very low). They will get a stem cell transplant from a half-compatible family member.

Életkor
21 years or younger at enrollment. Donors must be at least 18 years old.
Nem
All sexes can join.
A betegség stádiuma
Severe aplastic anemia or single lineage cytopenia: bone marrow cellularity < 25% or low for age, plus at least one of: neutrophils < 0.5 x10^9/L, platelets < 20 x10^9/L or needing platelet transfusions, hemoglobin <8g/dL or needing red blood cell transfusions.
Korábbi kezelés
Must have failed at least one course of immunosuppressive therapy (IST), with no response after at least 3 months or a relapse. People with very severe aplastic anemia do not need to have tried IST first. No sibling donor or 10/10 unrelated donor with the same tissue type available in time. A half-compatible (≥ 3 of 6) family donor is needed. No prior allogeneic stem cell transplant or solid organ transplant. No Alemtuzumab or ATG within 2 weeks of enrollment.
Biomarker vagy leletérték
Fanconi anemia must be ruled out by diepoxybutane (DEB) or similar testing. No anti-donor HLA antibodies.

A részvétel fő kizáró okai

  • Fanconi anemia, dyskeratosis congenita, or myelodysplastic syndrome (MDS) or its early signs such as Monosomy 7
  • Prior stem cell transplant from a donor or prior solid organ transplant
  • Uncontrolled bacterial, viral or fungal infection
  • Pregnant or breastfeeding
  • Past cancer, with some exceptions such as removed basal cell skin cancer or cancer treated more than 5 years ago

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Age less than or equal to 21 years at time of enrollment
  • Confirmed diagnosis of SAA or a single lineage cytopenia; (a) SAA or single lineage cytopenia will be defined as follows:; i. Bone marrow cellularity < 25% or hypocellular marrow for age, AND; ii. One or more of the following (in peripheral blood): (i) Neutrophils < 0.5 x10\^9/L (ii) Platelets < 20 x10\^9/L, or platelet transfusion dependence (iii) Hemoglobin <8g/dL, or red blood cell transfusion dependence
  • Does not have a suitable HLA-matched sibling donor (MSD) or volunteer 10/10 HLA-matched unrelated donor (MUD) available in the necessary time for progenitor cell donation
  • Failed at least one trial of immunosuppressive therapy (IST) by being refractory (persistence of severe cytopenias and fulfillment of SAA disease criteria at least 3 months after initial IST) or having relapsed (initial improvement of cytopenias after first-line IST but then a later return to fulfillment of SAA disease criteria when IST is decreased or ceased). IST could have included ATG based regimens, calcineurin inhibitors and/or other higher dose therapy directed at the treatment of primary SAA. Patients with very severe aplastic anemia who are likely not to benefit from IST do not need to have failed a trial of IST and can proceed directly to HCT if they meet the rest of the criteria
  • Has a suitable single haplotype matched (≥ 3 of 6) family member donor
  • Patient and/or legal guardian must sign informed consent for HCT
  • Adequate organ function defined as:; Left ventricular ejection fraction > 40% or shortening fraction ≥ 25%; Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml/ min/1.73m2; Forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry; ≥ 92% on room air if patient is unable to perform pulmonary function testing; Karnofsky or Lansky (age-dependent) performance score ≥ 50; Bilirubin ≤ 3 times the upper limit of normal for age; Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age
  • Females and males of childbearing potential must agree to practice 2 effective methods of contraception at the same time or agree to abstinence until after the last dose of chemotherapy has been administered
  • At least single haplotype matched (≥ 3 of 6) family member
  • At least 18 years of age
  • HIV negative
  • Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)
  • Not breast feeding
  • Related donors must be ruled out for telomere disease by appropriate clinical and diagnostic measures (for example, clinical evaluation, telomere length testing, genetic testing, and/or bone marrow examination)
  • The HAPLO donor and/or legal guardian must be able to sign informed consent documents
  • The potential HAPLO donor must be willing and able to donate PBSCs

Ki nem vehet részt

  • Presence of anti-donor HLA antibodies (positive anti-donor HLA antibody is defined as a positive cross-match test of any titer by complement- dependent cytotoxicity or flow cytometric testing or the presence of anti- donor HLA antibody to the high expression loci HLA-A, B, C, DRB1, or DPB1 with mean fluorescence intensity (MFI) > 1000 by solid phase immunoassay)
  • Prior allogeneic hematopoietic cell transplant
  • Prior solid organ transplant
  • Clonal cytogenetic abnormalities consistent with pre-myelodysplastic syndrome (pre- MDS) or MDS on marrow examination (e.g. Monosomy 7)
  • Diagnosis of myelodysplastic syndrome (MDS)
  • Uncontrolled bacterial, viral, or fungal infection at the time of enrollment. Uncontrolled is defined as progression or no clinical improvement on appropriate medical treatment
  • Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent > 5 years previously will be allowed. Cancer treated with curative intent ≤ 5 years previously will not be allowed unless approved by the PI
  • Diagnosis of Fanconi anemia. Fanconi anemia must be excluded by diepoxybutane (DEB) or equivalent testing
  • Known clinical or genetic diagnosis of dyskeratosis congenita
  • Known life-threatening reaction (i.e., anaphylaxis) to ATG that would prohibit use for the patient
  • Female patients who are pregnant (per institutional practice) or breast- feeding
  • Alemtuzumab or ATG within 2 weeks of enrollment

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • St. Jude Children's Research HospitalMemphis, Egyesült ÁllamokContact: Amr Qudeimat, MDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a prospective, single center phase II clinical trial in which patients with Severe Aplastic Anemia (SAA) ) will receive a haploidentical transplantation. The purpose of this study is to learn more about newer methods of transplanting blood forming cells donated by a family member that is not fully matched to the patient. This includes studying the effects of the chemotherapy, radiation, the transplanted cell product and additional white blood cell (lymphocyte) infusions on the patient's body, disease and overall survival. The primary objective is to assess the rate of engraftment at 30 days and overall survival (OS) and event free survival (EFS) at 1 year post-hematopoietic cell transplantation (HCT).

A teljes eredeti leírásKevesebb

Primary Objectives

* To estimate the rate of engraftment at 30 days after TCR αβ+ T-cell-depleted graft infusion in patients receiving a single dose of post graft infusion cyclophosphamide. * To estimate the overall survival and event free survival at 1-year post transplantation.

Secondary Objectives

* To calculate the incidence of acute and chronic GVHD after HCT. * To calculate the rate of secondary graft rejection at 1-year post transplantation * To calculate the cumulative incidence of viral reactivation (CMV, EBV and adenovirus). * To describe the immune reconstitution after TCR αβ+ T-cell-depleted graft infusion at 1 month, 3 months, 6 months, 9 months, and 1 year.

Exploratory Objectives

* To longitudinally assess the phenotype and epigenetic profile of T-cells in SAA patients receiving HCT for SAA. * To assess the phenotype and epigenetic profile of T-cells in DLI administered to SAA patients post HCT. * To longitudinally assess CD8 T cell differentiation status in SAA patients using an epigenetic atlas of human CD8 T cell differentiation. * To examine the effector functions and proliferative capacity of CD8 T cells isolated from SAA patients before and after DLI. * Quantify donor derived Treg cells at different time points in patients received HCT. * Determine Treg activation status at different stages after HCT. * Are specific features of the DLI product associated with particular immune repertoire profiles post-transplant? * How does the diversity and functional profile of the DLI product alter the response to pathogens in the recipient? * Do baseline features of the recipient's innate and adaptive immune cells correlate with post-transplant immune repertoires and response profiles?

A vizsgálat csoportja

  • Haploidentical HCTA vizsgált kezelés

    To assess the safety and efficacy of haploidentical donor transplantation for patients with severe aplastic anemia who lack an available HLA-matched donor. The goal of this study is to develop a novel, reduced-toxicity, post-transplant pharmacologic immunosuppression (GVHD prophylaxis)- free, highly tolerogenic haploidentical transplant regimen that is associated with few post- transplant complications or late toxicities and is available promptly to all patients, irrespective of matched donor availability. Cells for infusion are prepared using the CliniMACS System.

    Kezelés: Anti-Thymocyte Globulin (Rabbit), Fludarabine, Cyclophosphamide, Mesna, G-CSF, Total Lymphoid Irradiation (TLI), CliniMACS, HPC, A Infusion és CD45RA-depleted DLI

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. szeptember 16.